Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

1.450 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aprea Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics: Q4 Earnings Insights
 
Via Benzinga
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
From Aprea Therapeutics
Via GlobeNewswire
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024
APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovation 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
APRE stock results show that Aprea Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?
FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor) 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
From Aprea Therapeutics
Via GlobeNewswire
A Look Into Healthcare Sector Value Stocks
 
Via Benzinga
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ET 
From Aprea Therapeutics
Via GlobeNewswire
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
From Aprea Therapeutics
Via GlobeNewswire
5 Value Stocks To Watch In The Healthcare Sector
 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
 
Via Benzinga
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
From Aprea Therapeutics
Via GlobeNewswire
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
From Aprea Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.